OncoGenex Pharmaceuticals (OGXI) today announced results from the Phase III SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer (CRPC), compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p value 0.207). The adverse events observed were similar to custirsen's known adverse event profile.
Clearly, this was not the expected outcome, Oncogenex's market cap has been cut by more than -58% at the time of this writing. No new or unexpected adverse events were reported.
This increased benefit in the control arm is suspected to be due to the fact that 3 potent new agents have been approved since the